Antagonism of thromboxane receptors by diclofenac and lumiracoxib. 2007

E Selg, and C Buccellati, and M Andersson, and G E Rovati, and M Ezinga, and A Sala, and A-K Larsson, and M Ambrosio, and E Ambrosio, and L Låstbom, and V Capra, and B Dahlén, and A Ryrfeldt, and G C Folco, and S-E Dahlén
Division of Physiology, Centre for Allergy Research, The National Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.

OBJECTIVE Non-steroidal anti-inflammatory drugs (NSAIDs) are analgesic and anti-inflammatory by virtue of inhibition of the cyclooxygenase (COX) reaction that initiates biosynthesis of prostaglandins. Findings in a pulmonary pharmacology project gave rise to the hypothesis that certain members of the NSAID class might also be antagonists of the thromboxane (TP) receptor. METHODS Functional responses due to activation of the TP receptor were studied in isolated airway and vascular smooth muscle preparations from guinea pigs and rats as well as in human platelets. Receptor binding and activation of the TP receptor was studied in HEK293 cells. RESULTS Diclofenac concentration-dependently and selectively inhibited the contraction responses to TP receptor agonists such as prostaglandin D2 and U-46619 in the tested smooth muscle preparations and the aggregation of human platelets. The competitive antagonism of the TP receptor was confirmed by binding studies and at the level of signal transduction. The selective COX-2 inhibitor lumiracoxib shared this activity profile, whereas a number of standard NSAIDs and other selective COX-2 inhibitors did not. CONCLUSIONS Diclofenac and lumiracoxib, in addition to being COX unselective and highly COX-2 selective inhibitors, respectively, displayed a previously unknown pharmacological activity, namely TP receptor antagonism. Development of COX-2 selective inhibitors with dual activity as potent TP antagonists may lead to coxibs with improved cardiovascular safety, as the TP receptor mediates cardiovascular effects of thromboxane A2 and isoprostanes.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009131 Muscle, Smooth, Vascular The nonstriated involuntary muscle tissue of blood vessels. Vascular Smooth Muscle,Muscle, Vascular Smooth,Muscles, Vascular Smooth,Smooth Muscle, Vascular,Smooth Muscles, Vascular,Vascular Smooth Muscles
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D001792 Blood Platelets Non-nucleated disk-shaped cells formed in the megakaryocyte and found in the blood of all mammals. They are mainly involved in blood coagulation. Platelets,Thrombocytes,Blood Platelet,Platelet,Platelet, Blood,Platelets, Blood,Thrombocyte
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D004008 Diclofenac A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt. Diclophenac,Dichlofenal,Diclofenac Potassium,Diclofenac Sodium,Diclonate P,Dicrofenac,Feloran,GP-45,840,Novapirina,Orthofen,Orthophen,Ortofen,SR-38,Sodium Diclofenac,Voltaren,Voltarol,Diclofenac, Sodium,GP 45,840,GP45,840,SR 38,SR38
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005260 Female Females
D006168 Guinea Pigs A common name used for the genus Cavia. The most common species is Cavia porcellus which is the domesticated guinea pig used for pets and biomedical research. Cavia,Cavia porcellus,Guinea Pig,Pig, Guinea,Pigs, Guinea

Related Publications

E Selg, and C Buccellati, and M Andersson, and G E Rovati, and M Ezinga, and A Sala, and A-K Larsson, and M Ambrosio, and E Ambrosio, and L Låstbom, and V Capra, and B Dahlén, and A Ryrfeldt, and G C Folco, and S-E Dahlén
March 1985, British journal of pharmacology,
E Selg, and C Buccellati, and M Andersson, and G E Rovati, and M Ezinga, and A Sala, and A-K Larsson, and M Ambrosio, and E Ambrosio, and L Låstbom, and V Capra, and B Dahlén, and A Ryrfeldt, and G C Folco, and S-E Dahlén
January 1991, Trends in cardiovascular medicine,
E Selg, and C Buccellati, and M Andersson, and G E Rovati, and M Ezinga, and A Sala, and A-K Larsson, and M Ambrosio, and E Ambrosio, and L Låstbom, and V Capra, and B Dahlén, and A Ryrfeldt, and G C Folco, and S-E Dahlén
January 1991, Chirality,
E Selg, and C Buccellati, and M Andersson, and G E Rovati, and M Ezinga, and A Sala, and A-K Larsson, and M Ambrosio, and E Ambrosio, and L Låstbom, and V Capra, and B Dahlén, and A Ryrfeldt, and G C Folco, and S-E Dahlén
January 1987, European journal of pharmacology,
E Selg, and C Buccellati, and M Andersson, and G E Rovati, and M Ezinga, and A Sala, and A-K Larsson, and M Ambrosio, and E Ambrosio, and L Låstbom, and V Capra, and B Dahlén, and A Ryrfeldt, and G C Folco, and S-E Dahlén
January 1990, Circulation,
E Selg, and C Buccellati, and M Andersson, and G E Rovati, and M Ezinga, and A Sala, and A-K Larsson, and M Ambrosio, and E Ambrosio, and L Låstbom, and V Capra, and B Dahlén, and A Ryrfeldt, and G C Folco, and S-E Dahlén
January 1987, Advances in prostaglandin, thromboxane, and leukotriene research,
E Selg, and C Buccellati, and M Andersson, and G E Rovati, and M Ezinga, and A Sala, and A-K Larsson, and M Ambrosio, and E Ambrosio, and L Låstbom, and V Capra, and B Dahlén, and A Ryrfeldt, and G C Folco, and S-E Dahlén
August 1989, The New England journal of medicine,
E Selg, and C Buccellati, and M Andersson, and G E Rovati, and M Ezinga, and A Sala, and A-K Larsson, and M Ambrosio, and E Ambrosio, and L Låstbom, and V Capra, and B Dahlén, and A Ryrfeldt, and G C Folco, and S-E Dahlén
July 1997, Lancet (London, England),
E Selg, and C Buccellati, and M Andersson, and G E Rovati, and M Ezinga, and A Sala, and A-K Larsson, and M Ambrosio, and E Ambrosio, and L Låstbom, and V Capra, and B Dahlén, and A Ryrfeldt, and G C Folco, and S-E Dahlén
January 2005, Circulation,
E Selg, and C Buccellati, and M Andersson, and G E Rovati, and M Ezinga, and A Sala, and A-K Larsson, and M Ambrosio, and E Ambrosio, and L Låstbom, and V Capra, and B Dahlén, and A Ryrfeldt, and G C Folco, and S-E Dahlén
February 2009, Journal of agricultural and food chemistry,
Copied contents to your clipboard!